We are your pathology experts for reducing errors, navigating samples to correct tests and maximizing results.
Our Team at TruCore Pathology is committed to extracting the maximum amount of information possible from each needle core. We achieve this by applying new tissue preparation technology and molecular analysis pathways while reducing errors known as “QNS rates” (Quantity Not Sufficient). To successfully integrate molecular pathology and reduce QNS rates, the pathologist must correctly assess and navigate tissue on behalf of the urologist. Here’s an example:
Currently, when a urologist reads the diagnosis “PROSTATIC ADENOCARCINOMA, ACINAR TYPE, GLEASON SCORE 6(3+3), INVOLVING 5% OF TOTAL CORE VOLUME”, and desires to order molecular pathology, he/she really has no way of knowing just how many malignant glands are present. Is it packed or sparse? Is pathology cutting into the tumor or out of it? Which core should be sent; the one with highest grade or the one with the highest amount of cancerous tissue? Can multiple cores be combined to improve chances? While seemingly simple, the answers to these questions play a dramatic role in determining whether a patient gets a molecular result that can drastically improve a treatment plan and/or lead to a decrease in QNS rates.
With TrūCore Pathology, we typically reduce QNS rates from 30% to under 3%. We work closely with urologists to understand how cancers behave, determine best course(s) of treatment, virtually eliminate errors and streamline analysis right to your door. We get the results you and your patients need and deserve.
We use the latest state-of-the-art tissue preparation technology that delivers larger, higher quality samples that increase cancer detection
Our Team of Board Certified Anatomic, Clinical and Cytopathologists are trained Molecular Specialists with a dedicated Genitourinary focus